In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

The SELECT trial previously reported a 20% reduction in major adverse cardiovascular
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …

Abstract Background/Objective There are limited real-world studies assessing semaglutide
weight loss and associated comorbidity and metabolic outcomes over periods≥ 6 months …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease
associated with various health complications and increased mortality. Lifestyle modifications …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …